<?xml version="1.0" encoding="UTF-8"?>
<p id="par0110">Twenty BSAAs are undergoing surveillance studies (phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe, mycophenolic acid, nitazoxanide and rapamycin progressed to phase IV studies without approvals from national or international authorities (NCT01779570, NCT02058173, NCT02564471, NCT00821587, NCT03360682, NCT02328963, NCT02768545, NCT01624948, NCT01770483, NCT02683291, NCT01624948, NCT01469884, NCT03901001, NCT01412515, NCT02990312).</p>
